Stereotactic ablative radiotherapy for hepatocellular carcinoma with pencil beam scanning proton therapy: Initial results from a prospective phase II trial
Jonathan B. Ashman(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), R.S. Bhangoo(Mayo Clinic Hospital), Terence T. Sio(The University of Texas MD Anderson Cancer Center), William G. Rule(Mayo Clinic in Arizona), Nicole Thomas(WinnMed), Michael G. Haddock(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Molly M. Voss(Mayo Clinic in Arizona), Kumar Sandrasegaran, Mitesh J. Borad(Jacksonville College)
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423